What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there…”In the company’s words, NCT06632262 on ClinicalTrials.gov
- Tested for
- HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors, Achondroplasia
- Main trialPhase 2
- “The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations”In the company’s words, NCT06632262 on ClinicalTrials.gov
Other drugs for Urothelial Carcinoma
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
Coming up2
- 15 Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Nov 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Nov 2029 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | |
| Phase 1/2Not yet recruiting | 15 Dec 2028 | A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia | |
| Phase 1Unknown | 30 Apr 2025 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 30 Jul 2025 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026